FAQ on Kairos Pharma Ltd.'s Phase 2 Study of Prostate Cancer Drug ENV-105

What is ENV-105 and what is its purpose?

ENV-105 is a first-in-class CD105 antagonist developed by Kairos Pharma Ltd. to target CD105, a protein identified as a key driver of resistance to various cancer treatments, aiming to reverse drug resistance and restore the effectiveness of standard therapies in multiple cancer types.

What were the results of the Phase 2 trial for ENV-105?

The interim safety results from the Phase 2 trial showed no dose-limiting toxicities or unexpected adverse events in the first ten patients, and no Grade 3 or 4 toxicities were observed, indicating that ENV-105 was well tolerated when combined with apalutamide, a standard hormone therapy.

Where is the Phase 2 trial for ENV-105 being conducted?

The 100-patient trial is underway at Cedars-Sinai, City of Hope, and Huntsman Cancer Center.

When are the interim efficacy data for the Phase 2 trial expected?

Interim efficacy data are expected in September 2025.

What are Kairos Pharma Ltd.’s next steps following the Phase 2 trial?

Kairos plans to engage regulators on a potential Phase 3 study based on the results of the Phase 2 trial.

How does ENV-105 work in treating cancer?

ENV-105 targets CD105, a protein that elevates in response to standard therapy leading to resistance and disease relapse, aiming to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.

What is Kairos Pharma Ltd.’s focus in oncology therapeutics?

Kairos Pharma Ltd. focuses on utilizing structural biology to overcome drug resistance and immune suppression in cancer, with its lead candidate ENV-105 targeting CD105 to address significant unmet medical needs in cancer treatment.

Where can I find more information about Kairos Pharma Ltd. and its studies?

For more information, visit the company’s website at www.KairosPharma.com or the latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA.